

CLAIMS

1. Use of an anti-HER2 antibody-drug conjugate in the preparation of a medicament for treating cancer, wherein the anti-HER2 antibody-drug conjugate is to be administered in combination with an ATR inhibitor, and wherein the anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A represents the connecting position to an antibody, is conjugated to an anti-HER2 antibody via a thioether bond.

2. The use according to claim 1, wherein the ATR inhibitor is a compound represented by the following formula (I):





(I)


wherein:


R^1 is selected from morpholin-4-yl and 3-methylmorpholin-4-yl;

R^2 is



,


,


or


;

n is 0 or 1;

R^{2A}, **R^{2C}**, **R^{2E}** and **R^{2F}** each independently are hydrogen or methyl;

R^{2B} and **R^{2D}** each independently are hydrogen or methyl;

R^{2G} is selected from $-NHR^7$ and $-NHCOR^8$;

R^{2H} is fluoro;

R^3 is methyl;

R^4 and **R^5** are each independently hydrogen or methyl, or **R^4** and **R^5** together with the atom to which they are attached form Ring A;

Ring A is a C_{3-6}cycloalkyl or a saturated 4-6 membered heterocyclic ring containing one heteroatom selected from O and N;

R^6 is hydrogen;

R^7 is hydrogen or methyl;

R^8 is methyl,

or a pharmaceutically acceptable salt thereof.

3. The use according to claim 2 wherein, in formula (I), **R^4** and **R^5** together with the atom to which they are attached form


Ring A, and Ring A is a C_{3-6}cycloalkyl or a saturated 4-6 heterocyclic ring containing one heteroatom selected from O and N.

4. The use according to claim 2 or claim 3 wherein, in formula (I), Ring A is a cyclopropyl, tetrahydropyranyl or piperidinyl ring.

5. The use according to any one of claims 2 to 4 wherein, in formula (I), $\mathbf{R^{2A}}$ is hydrogen; $\mathbf{R^{2B}}$ is hydrogen; $\mathbf{R^{2C}}$ is hydrogen; $\mathbf{R^{2D}}$ is hydrogen; $\mathbf{R^{2E}}$ is hydrogen; and $\mathbf{R^{2F}}$ is hydrogen.

6. The use according to any one of claims 2 to 5 wherein, in formula (I), R^1 is 3-methylmorpholin-4-yl.

7. The use according to any one of claims 2 to 6 wherein the compound of formula (I) is a compound of formula (Ia):




(Ia)


or a pharmaceutically acceptable salt thereof.


8. The use according to claim 7 wherein, in formula (Ia):


Ring A is cyclopropyl ring;

R² is



,


,


or


;

n is 0 or 1;

R²ᴬ is hydrogen;

R²ᴮ is hydrogen;

R²ᶜ is hydrogen;

R²ᴰ is hydrogen;

R²ᴱ is hydrogen;

R²ᶠ is hydrogen;

R²ᴳ is -NHR⁷;


R²ᴴ is fluoro;

R³ is a methyl group;

R⁶ is hydrogen; and

R⁷ is hydrogen or methyl.

9. The use according to claim 2, wherein the ATR inhibitor is AZD6738 represented by the following formula:



or a pharmaceutically acceptable salt thereof.

10. The use according to any one of claims 1 to 9, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of an amino acid sequence represented by SEQ ID NO: 3, CDRH2 consisting of an amino acid sequence represented by SEQ ID NO: 4 and CDRH3 consisting of an amino acid sequence represented by SEQ ID NO: 5, and a light chain comprising CDRL1 consisting of an amino acid sequence represented by SEQ ID NO: 6, CDRL2 consisting of an amino acid sequence consisting of amino acid residues 1 to 3 of SEQ ID NO: 7 and CDRL3 consisting of an amino acid sequence represented by SEQ ID NO: 8.


11. The use according to any one of claims 1 to 9, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of an amino acid sequence represented by SEQ ID NO: 9 and a light chain comprising a light chain variable region consisting of an amino acid sequence represented by SEQ ID NO: 10.

12. The use according to any one of claims 1 to 9, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO: 1 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

13. The use according to any one of claims 1 to 9, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of an amino acid sequence represented by SEQ ID NO:

11 and a light chain consisting of an amino acid sequence represented by SEQ ID NO: 2.

14. The use according to any one of claims 1 to 13, wherein the anti-HER2 antibody-drug conjugate is represented by the following formula:



wherein 'Antibody' indicates the anti-HER2 antibody conjugated to the drug-linker via a thioether bond, and n indicates an average number of units of the drug-linker conjugated per antibody molecule in the antibody-drug conjugate, wherein n is in the range of from 7 to 8.

15. The use according to any one of claims 1 to 14, wherein the anti-HER2 antibody-drug conjugate is trastuzumab deruxtecan (DS-8201).

16. The use according to any one of claims 1 to 15, wherein the anti-HER2 antibody-drug conjugate and the ATR inhibitor are to be administered sequentially or simultaneously.

17. The use according to claim 1, wherein the cancer is at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head-and-neck cancer, esophagogastric junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, digestive tract stromal tumor, uterine cervix cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, corpus uteri carcinoma, kidney cancer, vulval cancer, thyroid cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

18. The use according to claim 1, wherein the cancer is breast cancer.

19. The use according to claim 18, wherein the breast cancer has a HER2 status score of IHC 3+.

20. The use according to claim 18, wherein the breast cancer is HER2 low-expressing breast cancer.

21. The use according to claim 18, wherein the breast cancer has a HER2 status score of IHC 2+.

22. The use according to claim 18, wherein the breast cancer has a HER2 status score of IHC 1+.

23. The use according to claim 18, wherein the breast cancer has a HER2 status score of IHC >0 and <1+.

24. The use according to claim 18, wherein the breast cancer is triple-negative breast cancer.

25. The use according to claim 1, wherein the cancer is gastric cancer.

26. The use according to claim 1, wherein the cancer is colorectal cancer.

27. The use according to claim 1, wherein the cancer is lung cancer.

28. The use according to claim 27, wherein the lung cancer is non-small cell lung cancer.

29. The use according to claim 1, wherein the cancer is pancreatic cancer.

30. The use according to claim 1, wherein the cancer is ovarian cancer.

31. The use according to claim 1, wherein the cancer is prostate cancer.

32. The use according to claim 1, wherein the cancer is kidney cancer.

33. The use according to claim 1, wherein cancer cells of the cancer are SLFN11-deficient.

34. The use according to claim 1, wherein SLFN11 expression is lower in the cancer cells of a patient relative to the patient’s SLFN11-expressing non-cancer cells.